These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1910098)

  • 1. Treatment of murine transitional cell carcinoma with intralesional interleukin 2 and murine interferon gamma.
    Sosnowski JT; DeHaven JI; Riggs DR; Lamm DL
    J Urol; 1991 Oct; 146(4):1164-7. PubMed ID: 1910098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential immunocytological evaluation of murine transitional cell carcinoma during intralesional bacillus Calmette-Guerin and interleukin-2 immunotherapy.
    Sosnowski JT; De Haven JI; Abraham FM; Riggs DR; Lamm DL
    J Urol; 1992 May; 147(5):1439-43. PubMed ID: 1569700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy.
    Riggs DR; Tarry WF; DeHaven JI; Sosnowski J; Lamm DL
    J Urol; 1992 Jan; 147(1):212-4. PubMed ID: 1729535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allium sativum (garlic) treatment for murine transitional cell carcinoma.
    Riggs DR; DeHaven JI; Lamm DL
    Cancer; 1997 May; 79(10):1987-94. PubMed ID: 9149027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of murine transitional cell carcinoma.
    Lamm DL; Reichert DF; Harris SC; Lucio RM
    J Urol; 1982 Nov; 128(5):1104-8. PubMed ID: 6757465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guerin and interleukin-2 for treatment of superficial bladder cancer.
    Cockett AT; Davis RS; Cos LR; Wheeless LL
    J Urol; 1991 Sep; 146(3):766-9; discussion 769-70. PubMed ID: 1875490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experimental study of the effects of hormonal therapy and intralesional injections of interleukin 2, activated macrophages on mouse prostate cancer models].
    Ikeda K
    Nihon Ika Daigaku Zasshi; 1994 Aug; 61(4):278-85. PubMed ID: 8083332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraluminal interleukin 2 and bacillus Calmette-Guerin for treatment of bladder cancer: a preliminary report.
    Merguerian PA; Donahue L; Cockett AT
    J Urol; 1987 Feb; 137(2):216-9. PubMed ID: 3492613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Gene therapy by in vivo interferon-gamma gene transfer to murine bladder tumor].
    Hashimura T; Ueda T; Hiura M; Yoshida O; Kawabata K; Watanabe Y; Takami M
    Hinyokika Kiyo; 1997 Nov; 43(11):809-13. PubMed ID: 9436027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
    Lee CF; Chang SY; Hsieh DS; Yu DS
    J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effect of interleukin 2 and bacillus Calmette-Guérin in the therapy of mice with transitional cell carcinoma.
    Ikemoto S; Kamizuru M; Wada S; Nishio S; Kishimoto T; Maekawa M
    Urol Int; 1991; 47(4):250-4. PubMed ID: 1781111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative effect of IL-6 on transitional cell carcinoma of the bladder. Insight into mechanisms of bacillus Calmette-Guerin immunotherapy.
    Alexandroff AB; Black J; Esuvaranathan K; James K
    Biochem Soc Trans; 1997 May; 25(2):270S. PubMed ID: 9191314
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
    Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
    J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effect of interleukin 2 and cyclophosphamide in therapy of mice with transitional cell carcinoma.
    Ikemoto S; Kamizuru M; Wada S; Hayahara N; Nishio S; Kishimoto T; Maekawa M
    Urology; 1992 Dec; 40(6):574-8. PubMed ID: 1466115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy of recombinant interleukin 2 in local treatment of superficial bladder tumors].
    Fujioka T; Shiraishi M; Tanji S; Sato S; Koike H; Aoki H; Suzuki K; Kumagai K; Banya Y; Kubo T
    Hinyokika Kiyo; 1988 Dec; 34(12):2115-9. PubMed ID: 3266444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells.
    Connor J; Bannerji R; Saito S; Heston W; Fair W; Gilboa E
    J Exp Med; 1993 Apr; 177(4):1127-34. PubMed ID: 8459207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
    Yu DS; Lee CF; Hsieh DS; Chang SY
    Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder.
    O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
    J Urol; 2004 Mar; 171(3):1336-42. PubMed ID: 14767344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
    Iigo M; Nishikata K; Nakajima Y; Moriyama M
    Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.